Abstract: Combination therapy is one of the best methods to manage the fatality rate in hepatocellular carcinoma (HCC). This study aimed to formulate a synergistic combination of synthetic and herbal compounds for the treatment of HCC as well as to elucidate a possible signalling mechanism. MTT and enzymatic assay were performed to determine the synergistic effect of drug combination (sorafenib, vitamin K1 and trans-chalcone) on HepG2 cell lines after intoxication with H 2 O 2 . Protein-protein interaction and docking studies were performed using Pathwaylinker2.0 and Schr€ odinger's software application to find out the mechanism of action and major targets for drug combination. The overall in vitro result showed that combination of trans-chalcone, vitamin K1 and sorafenib (10, 5 and 5 lM concentration, respectively) enhanced the resistance against oxidative stress generated by H 2 O 2 . The interaction studies helped in identification of few targets for docking of ligands (trans-chalcone, vitamin K1 and sorafenib). The study reports the synergistic effects of the formulation that can protect the cells from oxidative stress and restore normal levels of cellular enzymes in HepG2 cell line. We were able to determine the mechanism of action of herbal and synthetic formulation through in silico studies. Finally, docking studies confirmed potential targets for inhibition of hepatocarcinogenesis.
Hepatocellular carcinoma (HCC) is the second foremost cause of cancer-related mortality. Various techniques such as tumour resection and other chemotherapies are available, but combination therapy is the most effective and predominantly used treatment for HCC [1] . Combinatorial therapeutics have distinct features including synergistic effect of drugs, reduction in toxicity and minimization of drug resistance [2, 3] . Chemoprevention is an important phenomenon to maintain the balance between the proliferation and apoptotic conditions. An effective chemopreventive agent can reduce oxidative stress, minimize the cellular inflammation, optimize the metabolic energy and strengthen the cellular responses [4] .
Phytochemical compounds such as vitamin, flavonoids, chalcone and polyphenols can be used for effective cancer management. These compounds are potent antioxidants and exhibit antitumorigenic abilities [5, 6] . Sorafenib is an oral multikinase inhibitor (FDA-approved) for liver cancer. Longterm usage of sorafenib is toxic and leads to various neurological disorders, hypertension, haematologic abnormalities and nephrotoxicity [7, 8] . A study on doxorubicin and sorafenib are associated with increased toxicity and failed to improve the survival rate [9] . However, a review of antiangiogenic therapy for cancer treatment highlights that sorafenib combinations with naturally occurring compounds are more effective than sorafenib monotherapy [10] .
Hence, overall cancer management using a combination of plant-based secondary metabolites with sorafenib can be an effective way of treatment. In this study, we have used this concept and evaluated the effective dose of a combination of vitamin K1, trans-chalcone and sorafenib for HCC treatment against reactive oxygen species (ROS)-mediated tumorigenesis. We elucidated the possible mode of action of this combination using in silico studies. The network and docking studies determined a collective signalling pathway for combination treatment of HCC through sorafenib, vitamin K1 and trans-chalcone.
Method
In vitro studies.
Reagents and chemicals. Dulbecco's Modified Essential Medium (DMEM) 3-(4, 5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and foetal bovine serum (FBS) were purchased from HiMedia (India). Trypsin-EDTA (1, 10-phenanthrolinemonohydrate ophenanthrolineethylenediaminetetraacetic acid), dimethylsulfoxide (DMSO), antibiotic (penicillin-streptomycin solution), vitamin K1 and trans-chalcone were received from Sigma-Aldrich (St. Louis, MO U.S.A.). Hydrogen peroxide (H 2 O 2 ) was bought from Merck (Germany). Sorafenib was a gift from Cipla, India.
Cell culturing. HepG2 (human cancerous hepatocytes) cells were procured from National Centre for Cell Science (NCCS) Pune, Maharashtra, India. The cell line was cultivated in DMEM media and supplemented with 10% (v/v) foetal bovine serum and 0.01% antibiotic solution. The cells were incubated in 95% humidified air, and CO 2 was 5% at 37°C. H 2 O 2 stock solutions were freshly prepared using DMEM without FBS. The drugs were prepared by dissolving in Author for correspondence: Deepshikha Pande Katare, Proteomics & Translational Research Lab, Centre for Medical Biotechnology, Institute of Biotechnology, Amity University Uttar Pradesh, Noida, India (email dpkatare@amity.edu).
DMSO, and their concentration was kept below 0.1% for minimal toxicity.
MTT assay. The MTT assay was applied to assess the cell viability activity of the drugs individually and in combination. The total numbers of living cells were directly proportional to the total metabolic active cells. Cells were placed in 96-well flat-bottom plates for the assay. There were 5 9 10 3 cells in 200 lL of media. Cells were incubated for 24 hr at above-mentioned condition to adhere on the surface of the culture flask, and then pre-treated with different concentrations of trans-chalcone, vitamin K1 and sorafenib individually and in combination for 6 hr (table 1) . Afterwards, the cells were challenged with 25 mM H 2 O 2 for 2 hr. Blank wells contained only 200 lL of growth media. After completion of the incubation period, 20 lL MTT from stock of 5 mg/mL was added to each well and incubated for 3 hr. Subsequently, the media was removed and 100 lL DMSO added to each well for solubilization of formazan. The plates were incubated for 30 min for colour development. Optical density (OD) of developed colour was measured by an ELISA reader at a wavelength of 660 and 550 nm, respectively.
For the other experiments, 1 9 10 5 HepG2 cells were seeded in tissue cell culture plates (60-mm T flask). After overnight incubation the media was transferred and the cells were treated with different concentration of drug combinations for 6hr. Later on, the cells were washed twice with serum-free medium and then exposed to 25 mM H 2 O 2 for 2 hr. Further, the cells were detached from the T flask surface by trypsinization process (0.25% trypsin-EDTA), washed twice in prewarmed PBS (pH 7.2) and then resuspended in PBS. The cells were then lysed through sonication, and the supernatant was used for enzymatic and antioxidant assay.
Biochemical assay. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), triglyceride (TGL) and lactate dehydrogenase (LDH), albumin and bilirubin assays were performed using diagnostic kits procured from Span diagnostic and the procedure followed as described in the manufacturer's manual. Total protein concentration was assayed using the Bradford method [11] .
Antioxidant assay. To determine antioxidant activity, the lipid peroxidation assay was performed using modified thiobarbituric acidreactive substance (TBARS) assay according to the modified Wright et al., method [12] . The reaction mixture of 3 mL was prepared using 0.15 mL of 10% tissue homogenate, 0.70 mL of 0.67% thiobarbituric acid in PBS, 18 lL of 10 mM butylated hydroxytoluene (BHT) in ethanol and 2.130 mL of 1% orthophosphoric acid. The whole reaction mixture was incubated at 90°C for 45 min. Thereafter, the tubes were cooled and centrifuged at 3000 rpm for 5 min and the supernatant collected. Absorbance of the colour was recorded at 535 nm. The rate of lipid peroxidation was expressed as nmol of malondialdehyde (MDA) formed/mg protein/min.
In silico studies.
Literature mining for selection of proteins. An extensive literature survey was carried out to identify proteins, which were differentially expressed in the presence of sorafenib, vitamin K1 and trans-chalcone (table 2) . Collected proteins were checked theoretically for their participation in hepatocarcinogenesis in various related research articles. The accession numbers for collected proteins were retrieved from UniprotKB database (http://www.uniprot.org/). Special care was taken to collect only manually curate, non-redundant and reviewed human proteins.
Generation of protein-protein interaction network. Various databases such as STRING, BioGrid and DIP were used to create a primary protein-protein interaction network between the individual nine proteins and their neighbours. Later, all the nine proteins and their neighbours were given as an input to Pathwaylinker2.0 (http://pathwa ylinker.org/) to create the final interaction network among the query proteins and their neighbours. The master network was later used to find out mostly followed signalling pathways and processes, when these proteins are differentially co-expressed in the human body. The results were also supported by statistically calculated p-values.
Screening of possible targets for docking. The master network was studied for the screening of the pathways (comprised of query and their neighbouring proteins) indicating progression in liver cancer. These processes majorly consisted of protein targets for sorafenib, vitamin K1 and trans-chalcone. Thus, a hypothesis was developed on the role of these proteins and their possible effects after binding to the above-mentioned compounds. These proteins were later selected for binding and docking analysis. Docking studies. Ligand preparation was made in Maestro9.6 workspace. Ligands were sketched using 2D-Sketcher, and later, their low-energy poses were generated using LigPrep2.8 module of the Schrodinger software. Simultaneously, the target protein receptors were retrieved from the Protein Data Bank (PDB) directly in the protein preparation wizard of Maestro9.6 Interface. Prime3.5 module was used to model their missing atoms and disarrayed side chains. Extra water molecules were also removed. A Glide6.1 module with Extra Precision (XP) strategy was used for docking.
Results
MTT assay. In this study, we have used sorafenib, transchalcone and vitamin K1 individually and in combination. Cell survival rate after H 2 O 2 treatment was recorded at 17.6%. In individual treatment, at their low doses (5 lM), cell viability was 85.14% (p < 0.01), 80.15% (p < 0.01) and 84.32% (p < 0.01) for trans-chalcone, vitamin K1 and sorafenib, respectively. Whereas, at higher concentration (10 lM), the above-mentioned drugs showed increased cell Albumin, bilirubin and total protein levels. When the cells were exposed to toxicant, albumin level was drastically reduced (0.9 g/L), whereas the bilirubin level (0.98 mg/dL) increased as compared to normal cells. Pre-treatment of individual drugs at lower (5 lM) dose of trans-chalcone, vitamin K1 and sorafenib exhibited an increase in albumin level by 1.17, 2.18 and 1.14 g/L, while bilirubin level decreased to 0.57, 0.63, 0.54 mg/dL, respectively. At a higher dose (10 lM) for each drug, the albumin and bilirubin levels changed in a dose-dependent manner as compared to the toxicant group (p < 0.01). We observed that combination treatment in the ratio of 1 
4).
Lipid peroxidase assay. A notable amount of TBARS (thiobarbituric acid-reactive substance) formation (0.875 nmol/ mg protein) observed due to higher oxidative stress caused by H 2 O 2 intoxication. This level decreased with a lower dose (5 lM) of each drug (trans-chalcone and sorafenib) by 0.761 and 0.802 nmol/mg protein, respectively. At a higher concentration, each drug showed reduction in lipid peroxidase activity in a dose-dependent manner. The combined ratio of trans-chalcone and sorafenib at both 1:1 and 1:0.5 ratio exhibited reduction in ROS to 0.521 and 0.471 nmol/mg protein, respectively, as compared to the toxicant group (p < 0.01; fig. 5 ).
Interaction studies.
We identified differentially expressed proteins involved in hepatocarcinogenesis through an extensive literature search. We also used a number of proteins from an established HCC model developed in our laboratory (unpublished data Deepshikha Pande Katare (DPK)). Overall, we were only interested in proteins affected by sorafenib, vitamin K1 and trans-chalcone. A total of 776 neighbours were observed for nine query proteins (table 2) . This master network represents the crosstalk between the query and neighbouring proteins. This crosstalk could be the result of their involvement in similar pathways or their intermittent connections in various pathways ( fig. 6 ). Probability of occurrence of cancer pathway in the total dataset was observed to be 7.7e-110. This p-value indicates that the query proteins and their neighbours have a role in cancer pathway and can be used for screening targets for designing cancer medication.
Docking studies.
Molecular docking showed the binding between ligands and receptors. Different poses were allowed to dock with respective receptors and were analysed according to their Glide Score. Sorafenib showed highest affinity (À12.670) with vascular endothelial growth factor receptor (VEGFR). Vitamin K1 and trans-chalcone showed affinity with steroid/xenobiotic receptor (SXR) by À11.051 and À9.86, respectively (table 3 and fig. 7 ). The network and docking studies showed the overall signalling pathway for combination treatment of HCC through sorafenib, vitamin K1 and trans-chalcone ( fig. 8 ).
Discussion
HepG2 cell line has been utilized by researchers to investigate metabolic and toxic effect of xenobiotics on liver [13] . H 2 O 2 has the ability to generate reactive oxygen species (ROS), DNA damage, alteration in homoeostasis and formation of DNA adducts that leads to tumorigenesis [14, 15] . It has been seen that ROS level is comparatively high in oncogenic cells and promotes signalling pathways such as NF-kB (Nuclear factor-kappa B) and AKT (serine-/threonine-specific protein kinase) in carcinogenesis [16] . The intracellular ROS scavenging can trigger apoptosis and boost cell cycle arrest [17] . Long-term usage of sorafenib has an adverse effect in cancer patients [8] . We used plant-based compounds, that is vitamin K1 and trans-chalcone indifferent ratio to overcome this disadvantage. After several permutations and combinations, we observed that a 5-lM concentration of sorafenib in combination with higher doses trans-chalcone and vitamin K1 was effective. Our study reports that combination pre-treatment with transchalcone, vitamin K1 and sorafenib in a ratio of 1:1:1 and 1:0.5:0.5 exhibits improved cell protection in comparison with their individual doses. The overall LPO, MTT and LDH assay reinforce the idea that a 1:0.5:0.5 ratio of trans-chalcone, vitamin K1 and sorafenib has an impressive ability to protect the cells from oxidative stress produced by H 2 O 2 . Similarly, other studies also reported that a 20-lM concentration of trans-chalcone has an effective protection against oxidative stress in HepG2 cells [13, 18] . Some studies on vitamin K1 also reported anti-tumorigenic activity in various cell lines like liver, colon, lung and stomach [19] . In our investigation, a combination of these two phytochemicals with sorafenib showed cytoprotection against toxic exposure in a similar manner. Although we chose a low concentration of sorafenib (5 lM) with plant-based compounds, vitamin K1 and trans-chalcone (5 and 10 lM respectively), the cytoprotective effect of the combination was relatively high as compared to their individual dose. This shows the synergetic effect of the combination in the cell line model.
Marker enzymes of liver function such as AST, ALT, ALP and bilirubin are reported to be elevated in disease conditions, whereas the level of albumin and triglyceride decrease with carcinogenesis [20, 21] . Our findings are in accordance with To elucidate signalling pathways affected by combinatorial formulation, we performed in silico studies. A significant number of researchers have used networking and docking studies to identify new targets to support their wet-laboratory results [22] . Protein-protein interaction is a major factor in cell signalling, while docking studies may help to trace new drug targets. In our study, each drug utilized individual pathways for inhibition of carcinogenesis. The network and docking study determined the overall signalling pathway for combination treatment of HCC through sorafenib, vitamin K1 and trans-chalcone. Several reports also showed that each compound plays major roles in angiogenesis inhibition (VEGFR), cell proliferation inhibition (Protein kinase C) and ROS reduction, respectively [22, 23] . Vitamin K1, a ligand for steroid/xenobiotic receptor (SXR), reciprocally regulates nuclear factor-kappa B (NF-jB) and is also abundantly expressed in the liver [29] . Trans-chalcone has the ability to inhibit polymerization of b-tubulin in cytoskeleton formation. When our docking results were correlated with their results, it was observed that sorafenib might inhibit angiogenesis and cell proliferation via suppression of B-RAF, VEGFR and pT53 receptor. Similarly, vitamin K1 and trans-chalcone might decrease the ROS via binding with SXR. Therefore, from the docking studies and with high binding affinities between the ligand and receptors, it is hypothesized that the summation of this event might help in anti-angiogenic and antitumorigenic activities. The above findings conclude that sorafenib with herbal compounds can be effective in chemoprevention and cancer management by reducing the oxidative stress and normalizing the cellular enzymes. Combination of trans-chalcone, vitamin K1 and sorafenib in concentrations of 10, 5, 5 lM, respectively, improves the resistance against oxidative stress generated by H 2 O 2 . These analyses impose the idea of synergistic formulation for a safe and effective chemoprevention and HCC management.
